EximBank and Antibiotice SA, one of the top players on pharmaceutical market, have concluded a financial agreement amounting at RON 60 M to be used for financing the current activity of the company in order to reach its business targets: increase production activity and sales, especially for export volumes, a press release informs. The financial package will be used by the pharmaceutical company to finance its current activity as well as re-finance a credit contracted form another commercial bank. “The partnership that we have concluded with Antibiotice proves our business strategic direction right when offering to the corporate segment a products and services portfolio at competitive prices level and attractive for the companies seeking business development solutions for medium and long term,” declared Traian Halalai, President of EximBank. Antibiotice S.A. is one of the most important Romanian exporters of pharmaceutical deliverables and Nystatin estimating a 20 per cent growth of export sales as compared to 2012 considering the expansion of the partnerships on USA market and other states as well. The estimated value of exports for this year amounts at USD 24 M out of which almost USD 5 M represents sales volumes for the USA market.